CEPI y Moderna aprovechan la tecnología ARNm para avanzar en la Misión de los 100 días

Contributed by: ACCESSWIRE

Logo

Tags

Healthcare & Pharmaceutical

Moderna, Inc.

NASDAQ:MRNA

Company Update

More Like This

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

PR Newswire associated0

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

PR Newswire associated0

Thirty-One mRNA Leaders Launch First Global Organization Dedicated to Advancing mRNA Medicines

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345